Making HT-1 Treatment Simpler

Hereditary tyrosinemia is an autosomal recessive genetic metabolic condition, one of the rare amino acid disorders typically detected through newborn screening. Affected patients lack the enzyme fumarylacetoacetate hydrolase (FAH), which is necessary to break down the amino acid tyrosine.

NITYR (nitisinone) tablets are a new option for treatment of hereditary tyrosinemia (HT-1). Your patients living with HT-1 may be unaware of this new option for nitisinone – the first in many years – or may have a number of questions regarding the difference compared to the current nitisinone on the market.